… of SHP2 mRNA is significantly increased in many primary leukemia specimens. The expression
of SHP2 and SHP2 mRNA in the leukemia patients … as a single agent for patients with …

… , orally bioavailable allosteric inhibitor of SHP2, a central node … A total of 104 patients were
dosed across three schedules: … Of the 80 efficacy evaluable patients, there was 1 CR (NF1 …

… Significance: MEK inhibitors show limited efficacy as single agents, in part because of the
rapid development of adaptive resistance. We find that SHP2/MEK inhibitor combinations …

… Here we present data from TNO155 single agent escalation. Results: As of 10/26/2020,
118 patients received TNO155 in variable schedules: once (QD; 1.5–70 mg; n = 55) or twice …

… the single agents. The results showed that combining two different but compatible SHP2
inhibitors (dual allosteric inhibitors) … that patients who are resistant to most kinase inhibitors have …

… As opposed to treating patients with a SHP2 inhibitor alone in dose escalation, each patient
with an oncogene-driven cancer was permitted the addition of matched targeted therapy …

… single-patient case reports describing anti-tumor response to immune checkpoint inhibition
in patients with MPNST: 1) a patient … Multiple clinical trials of SHP2 inhibitors as single agents…

… in patients with NSCLC harboring KRAS mutations. RMC-4630 continues to be tested as a
single agent in patients … This study is also open to patients with KRASG12C NSCLC who are …

… of patients. Therefore, we investigated whether combination with SHP2 inhibitors could
enhance MAPK inhibitor … , treatment with SHP2 inhibitors as a single agent might be an effective …

… SHP2 inhibitors is not expected to be affected by the EGFR T790M and C797S mutations,
even if they cooccur on the same DNA strand (in cis) as seen in some patients … single agents at …